KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) Interest Expenses (2016 - 2025)

Boston Scientific (BSX) has disclosed Interest Expenses for 17 consecutive years, with $90.0 million as the latest value for Q4 2025.

  • Quarterly Interest Expenses rose 12.5% to $90.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $349.0 million through Dec 2025, up 14.43% year-over-year, with the annual reading at $349.0 million for FY2025, 14.43% up from the prior year.
  • Interest Expenses hit $90.0 million in Q4 2025 for Boston Scientific, up from $87.0 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $279.0 million in Q1 2022 to a low of $63.0 million in Q3 2022.
  • Historically, Interest Expenses has averaged $86.6 million across 5 years, with a median of $79.5 million in 2024.
  • Biggest five-year swings in Interest Expenses: skyrocketed 240.24% in 2022 and later tumbled 76.7% in 2023.
  • Year by year, Interest Expenses stood at $87.0 million in 2021, then decreased by 26.44% to $64.0 million in 2022, then rose by 1.56% to $65.0 million in 2023, then increased by 23.08% to $80.0 million in 2024, then increased by 12.5% to $90.0 million in 2025.
  • Business Quant data shows Interest Expenses for BSX at $90.0 million in Q4 2025, $87.0 million in Q3 2025, and $90.0 million in Q2 2025.